Sumana Adak (Correspondent, Edinburgh):
A team of scientists from Oxford University have reassured the world about the discovery of the antidote to COVID-19 while the researchers around the world are terribly worried.
Researchers at the Jenner Institution of Oxford University in collaboration with AstraZeneca are quite optimistic to their discovery. The eyes of the whole world are now on Britain after the first and second episodes of the vaccine discovery were published in the journal ‘The Lancet’.
For the time being, after the application of this vaccine in the human body, it is known that there is a positive effect. “We’ve received two doses of this vaccine from 10 participants who have been really resistant to the disease, a great success,” said Pollard, a professor at the Jenner Institution.
The first phase trial in the UK began in the first week of April to test the coronavirus vaccine ChAdOx1 nCov-19. It is also interesting to note that this vaccine has another special feature which is its giant resistance.
Already Oxford University has signed an agreement with British pharmaceutical company AstraZeneca for the development, production and distribution of the COVID-19 vaccine, with the British government pledging £ 8 million from its funds to further accelerate the project.
Two methods have been used so far to prepare vaccines experimentally; the Jenner researchers have used the first being the most common and safest in the world market. So far it has been popular all over the world.
According to the conventional vaccine discovery method, the weakest part of the virus is applied to the body in the same way, activating its immune system against the virus, so that subsequent attacks can be prevented.
Researchers at the Jenner Institution are claiming success using the same method in inventing the COVID-19 vaccine. Although most factories around the world are able to make vaccines in this way, the only problem is that they require a lot of raw materials to produce them.
According to some experts, it takes more than hudge tons of raw material to make a vaccine suitable for one’s body, so it will not be difficult to understand that this method requires a lot of time to produce. And the second method is the use of RNA and DNA scientific technology.
Here our immune system is effective only when the body starts producing antigens. In this method, the cost of production of vaccines is a little less, but due to lack of proper infrastructure and vaccine needs to be stored at-80°Celsius, many experts believe that while it is possible to build infrastructure in the United Kingdom, it is often impossible to reach many other parts of the world quickly at this time.
In addition, for clinical tests, we need multiple trainers and skilled doctors, nurses, etc. with appropriate structure. So the amount of production in this method is also a little less. At present, most of the countries in the world are struggling with corona, in which case it is very difficult to build the infrastructure for clinical trials.
The World Health Organization (WHO) has announced an adaptive trial of the solution. All the experimental vaccines will be included in a clinical trial. The advantage of this is that vaccines that do not work will be dropped and effective vaccines will be listed.
WHO also said that the vaccine has to be administrated in the human body in three steps, though the first two steps have been shown to be effective, but it is also important to see how safe the vaccine is, as each vaccine has some side effects.
However, no side effects other than fatigue and headache have been reported so far after taking this vaccine. The vaccine can be more confirmed after a few more days of application in some people. So far, the vaccine has been able to develop antidote against the virus, but there is still some ambiguity as to whether it will only improve the immune system or completely prevent the disease.
In addition to Britain, trials of the vaccine have begun in Brazil and parts of Africa. AstraZeneca is very optimistic about this. So far the UK has agreed with the United States, Europe’s Inclusive Vaccine Alliance and the Serum Institute of India to supply 2 billion doses. Pollard who is associated with the project, added: ‘There is reason to be excited. There is evidence that this vaccine can prevent infection’. Therefore it’s just a matter of time to get the vaccine.